• Aclaris Therapeutics published Phase 1b results for ATI-052 in atopic dermatitis and asthma, supporting advancement into a staged Phase 2b program.
• At week eight, ATI-052 reduced eczema severity scores 58% from baseline versus 13% with placebo.
• In asthma, a single dose reduced fractional exhaled nitric oxide 59% by day 15 versus 15% with placebo.
• Lung function improved by a placebo-adjusted 200 milliliters at day 15 in the overall asthma population.
• Neither trial recorded serious treatment-emergent adverse events or discontinuations due to treatment-emergent adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.